Key Highlights
- TNGX shares skyrocketed 45% following the announcement of a 92% objective response rate in pancreatic cancer patients treated with vopimetostat combined with daraxonrasib
- The treatment combination demonstrated a perfect 100% disease control rate among 12 evaluable patients, with 90% remaining progression-free at the 6-month milestone
- An alternative pairing — vopimetostat with zoldonrasib — delivered a 52% objective response rate among 27 trial participants
- Safety profiles remained favorable for both combinations; no Grade 4 or 5 adverse reactions reported, zero treatment discontinuations
- The company intends to initiate Phase 3 testing of the vopimetostat/daraxonrasib combination for first-line MTAP-deleted pancreatic cancer during the second half of 2026
Shares of Tango Therapeutics (TNGX) surged 45% during Monday’s premarket session following the biotech company’s announcement of encouraging early-phase clinical trial results demonstrating that its drug combination effectively reduced tumor size in virtually all patients battling advanced pancreatic cancer.
Tango Therapeutics, Inc., TNGX
The standout figure: a remarkable 92% objective response rate observed in patients receiving vopimetostat alongside Revolution Medicines’ daraxonrasib. This translates to 11 out of 12 evaluable patients with metastatic pancreatic ductal adenocarcinoma showing positive responses to the therapy.
The combination therapy additionally achieved a complete 100% disease control rate. Nine out of the 11 responses received confirmation, while 90% of trial participants remained free from disease progression at the 6-month evaluation point.
The patient population consisted of individuals with second and third-line metastatic disease — meaning they had already undergone previous treatment regimens. More than 70% of participants presented with liver metastases.
Median progression-free survival remained unreached at the May 28 data cutoff date, which typically signals positive momentum during this phase of clinical development.
Trial participants received either 200mg or 250mg of vopimetostat daily, paired with 100mg of daraxonrasib administered once per day. The dataset encompassed 59 total patients spanning both pancreatic cancer and non-small cell lung cancer cohorts.
Alternative Combination Demonstrates Encouraging Results
Tango additionally unveiled findings from an alternative drug pairing — vopimetostat combined with Revolution’s zoldonrasib — involving 27 evaluable pancreatic cancer patients.
This treatment arm produced a 52% objective response rate alongside a 74% progression-free survival rate at 6 months. Tumor reduction occurred in 14 of the 27 participants.
While less dramatic than the daraxonrasib combination, these results further support vopimetostat’s therapeutic potential when paired with various combination partners.
Both treatment regimens exhibited favorable tolerability profiles. The majority of adverse events fell within Grade 1 or 2 categories. The daraxonrasib combination’s most frequently reported side effects included rash, stomatitis/mucositis, and diarrhea. Neither Grade 4 nor Grade 5 events emerged, and no participants withdrew from the study due to treatment-related complications.
Future Development Plans
Tango intends to progress vopimetostat combined with daraxonrasib into Phase 3 clinical development. The focus: first-line treatment for patients with MTAP-deleted pancreatic cancer.
The organization anticipates completing Phase 3 trial design during the latter half of 2026, subject to regulatory consultations.
MTAP deletions appear in approximately 40% of pancreatic cancer cases and roughly 15% of lung cancer diagnoses — representing a well-defined patient subset that provides the trial with precise genetic selection parameters.
These results emerge just one week following Revolution Medicines’ presentation of daraxonrasib data at ASCO, where the compound demonstrated a doubling of survival times in pancreatic cancer patients.
Tango’s vopimetostat represents an oral therapeutic specifically engineered to target cancer cells harboring MTAP deletions.
Revolution Medicines (RVMD) stock declined 4.15% during the trading session.
